Phio Pharmaceuticals Corp
PHIO
Company Profile
Business description
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Contact
11 Apex Drive
Suite 300A PMB 2006
MarlboroughMA01752
USAT: +1 508 767-3861
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
Small caps have outperformed blue chips this year. Here’s some opportunities outside the ASX100.
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.00 | 26.10 | 0.29% |
| CAC 40 | 8,097.75 | 16.99 | -0.21% |
| DAX 40 | 24,027.80 | 0.34 | -0.00% |
| Dow JONES (US) | 47,797.63 | 157.36 | -0.33% |
| FTSE 100 | 9,640.26 | 26.75 | -0.28% |
| HKSE | 25,765.36 | 319.72 | -1.23% |
| NASDAQ | 23,541.67 | 36.46 | -0.15% |
| Nikkei 225 | 50,581.94 | 90.07 | 0.18% |
| NZX 50 Index | 13,486.32 | 2.33 | 0.02% |
| S&P 500 | 6,850.96 | 19.44 | -0.28% |
| S&P/ASX 200 | 8,624.40 | 28.80 | 0.34% |
| SSE Composite Index | 3,924.08 | 21.27 | 0.55% |